— Why it moved
Why TCRT Stock More Than Doubled Today — October 13, 2026
Alaunos Therapeutics announced a biotech acquisition alongside a massive financing deal, sending a micro-float into absolute overdrive.
What moved TCRT stock
Alaunos Therapeutics is a clinical-stage oncology biotech firm. The company announced the acquisition of Velaris Therapeutics paired with a $350 million private placement. Headline readers piled in fast, completely ignoring the structural dilution attached to convertible preferred stock.
The mechanics
The stock sits on a tiny float of 1.89 million shares and a market cap under $2.7 million. Trading 256 million shares against that micro-float created absolute chaos before the eventual pullbacks.
TCRT by the numbers
The alert window
The alert dropped at 7:23 AM ET at $2.02. Early chasers had to sweat through a 25.2% drawdown down to $1.51. That shakeout gave way to a 296-minute run to the peak of $4.32 at 12:19 PM ET, offering a 113.9% maximum sellable window.
How TCRT's move ended
TCRT closed at $3.03, up 50.0% from the alert price. It gave back over a dollar from its peak as volume slowed. A massive funding deal on a micro-cap guarantees heavy dilution down the road.
The tell: Private placement headlines buy immediate morning volume, but convertible preferred stock always converts into downstream overhead supply.